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Elevated intratumoral interstitial fluid pressure (IFP) and tumour hypoxia are independent predictive factors for poor survival and
poor treatment response in cancer patients. However, the relationship between IFP and tumour hypoxia has not yet been clearly
established. Preclinical studies have shown that lowering IFP improves treatment response to cytotoxic therapy. Interstitial fluid
pressure can be reduced by inhibition of phosphorylated platelet-derived growth factor receptor-b (p-PDGFR-b), a tyrosine kinase
receptor frequently overexpressed in cancer stroma, and/or by inhibition of VEGF, a growth factor commonly overexpressed in
tumours overexpressing p-PDGFR-b. We hypothesised that Imatinib, a specific PDGFR-b inhibitor will, in addition to p-PDGFR-b
inhibition, downregulate VEGF, decrease IFP and improve tumour oxygenation. A549 human lung adenocarcinoma xenografts
overexpressing PDGFR-b were grown in nude mice. Tumour-bearing animals were randomised to control and treatment groups
(Imatinib 50mgkg
 1 via gavage for 4 days). Interstitial fluid pressure was measured in both groups before and after treatment. EF5, a
hypoxia marker, was administered 3h before being killed. Tumours were sectioned and stained for p-PDGFR-b, VEGF and EF5
binding. Stained sections were viewed with a fluorescence microscope and image analysis was performed. Imatinib treatment resulted
in significant reduction of p-PDGFR-b, VEGF and IFP. Tumour oxygenation was also significantly improved. This study shows that
p-PDGFR-b-overexpressing tumours can be effectively treated with Imatinib to decrease tumour IFP. Importantly, this is the first
study demonstrating that Imatinib treatment improves tumour oxygenation and downregulates tumour VEGF expression.
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Non-small-cell lung cancer (NSCLC) accounts for approximately
80% of all lung cancers and is the leading cause of cancer-related
deaths worldwide (Jemal et al, 2005). The response rate for first-
line therapy in NSCLC is 19% with 1- and 2-year survival rates
in the range of 30–36% and 10–16%, respectively (Schiller et al,
2002). Factors thought to contribute to poor tumour response to
chemotherapy and/or radiation therapy are limitations in drug
delivery resulting from elevated intratumoral interstitial fluid
pressure (IFP) (Stohrer et al, 2000) and reduced treatment
sensitivity due to tumour hypoxia (Brizel et al, 1997).
One of the physiological challenges in drug delivery to tumour
cells is its heterogeneous blood supply and abnormal micro-
vascular permeability that leads to increased IFP and poor drug
penetration. Elevated IFP is a hallmark of solid tumours and has
been identified as an independent predictor for poor radiation
treatment response in cervical cancer (Netti et al, 1996; Griffon-
Etienne et al, 1999; Milosevic et al, 2004).
In addition to IFP, tumour hypoxia has been shown to be an
independent predictor for local control and patient survival
following radiation therapy for carcinoma of the cervix
and head and neck cancer (Brizel et al, 1999; Birner et al, 2000;
Koukourakis et al, 2001; Bachtiary et al, 2003; Nordsmark and
Overgaard, 2004). Comparison of IFP and pO2 measurements in
patients with cervical cancer demonstrate that IFP is a stronger
predictor than hypoxia for pelvic recurrence and disease-free
survival (Milosevic et al, 2004). Although the relationship between
IFP and pO2 is not fully understood, hypoxia is believed
to be associated with an increased IFP in solid tumours (Taghian
et al, 2005).
Phosphorylated PDGFR-b, a stromal tyrosine kinase receptor,
is recognised as a strategic target for lowering IFP in tumours
overexpressing PDGFR-b. PDGFR-b is overexpressed in 50–80%
of patients with NSCLC (Kawai et al, 1997). When phosphorylated,
PDGFR-b contributes to increased IFP by enhanced stimulation of
stromal growth, which disrupts interstitial homeostasis (Heuchel
et al, 1999; Ostman, 2004) and by participation in tumour
angiogenesis (Pietras et al, 2001; Labrecque et al, 2005). Although
VEGF is the predominate angiogenic factor that promotes
endothelial cell (EC) proliferation, migration, vessel sprouting,
vessel remodelling and vascular permeability (Dvorak et al, 1995),
p-PDGFR-b is required for pericyte and smooth muscle cell
recruitment and for the subsequent completion of the angiogenic
process (Nykanen et al, 2005). Preclinical data have reported that
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sIFP can be reduced by p-PDGFR-b inhibition using Imatinib
(STI571, Gleevec
s, Novartis Pharmaceuticals) (Pietras et al, 2001).
Imatinib is a PDGFR-b-specific small-molecule tyrosine kinase
inhibitor. We hypothesised that Imatinib, as a consequence of
p-PDGFR-b inhibition, will affect angiogenesis, decrease IFP and
improve tumour oxygenation in an NSCLC xenograft.
MATERIALS AND METHODS
Animal NSCLC model
Adult female nude mice were used as host animals for xenograft
tumours. Tumours were grown from exponentially growing A549
cell cultures. The A549 cell line was derived from human lung
carcinoma and was purchased from ATCC. Cells were grown in
RPMI 1640 media supplemented with 5% bovine calf serum. Cells
(B5.0 10
5) suspended in 200ml of HBSS were injected sub-
cutaneously into the right hind limb of each mouse.
Tumour growth was monitored twice weekly until they reached
an average volume of 100mm
3. Tumour volume (V) was
determined by the following equation: V¼(L W
2) 0.5, where
L is the length and W is the width of the tumour. Tumour-bearing
animals were then randomised into control (saline) and treatment
groups. There were 10 animals in each treatment group. Imatinib
(STI571, Gleevec
s), 50mgkg
 1, was administered to tumour-
bearing mice once a day for 4 days. The study was repeated twice.
Imatinib was commercially obtained in a 100mg tablet form,
crushed and re-suspended in saline and given via gavage.
Animal experiments were approved by the Institutional
Committee on Research Animal Care and were performed in strict
accordance to the Interdisciplinary Principles and Guidelines for
the Use of Animals in Research, Marketing and Education (New
York Academy of Sciences, New York, NY, USA) and in
accordance with the UKCCCR guidelines (Anon, 1988).
IFP measurements
Animals were anaesthetised using nembutal (75mgkg
 1). Inter-
stitial fluid pressure measurements were performed for each
animal before and 3h after the last saline or Imatinib treatment.
Tumour IFP was measured using the wick-in-needle technique as
described previously (Boucher et al, 1991). A standard 23-gauge
needle filled with nylon floss and saline, supplemented with
50IEml
 1 of heparin, was inserted into the centre of the tumour
and connected to a pressure transducer (World Precision
Instruments Inc., Sarasota, Florida, USA). This set-up enabled
continuous and stable recording of fluid pressure. Fluid commu-
nication between the needle and the transducer was confirmed by
compression and decompression of the tubing during each
measurement. Tumour IFP was determined by calculating the
mean of two readings. Interstitial fluid pressure values in muscle
and subcutaneous tissue served as controls.
Hypoxia marker EF5
Mice received an intravenous (i.v.) injection (0.2ml of 10mM EF5)
of the hypoxia marker EF5 (2-(2-nitro-1H-imidazole-1-yl)-N-
(2,2,3,3,3-pentafluoropropyl) acetamide), generously provided by
Dr Cameron Koch, University of Pennsylvania, 3h before tumour
excision. After killing the animals, the tumour specimens were
removed and snap frozen in liquid nitrogen. Specimens were
stored at  801C until sectioned.
Immunohistochemical staining
Frozen specimens were cut into 10–12mm sections using a LEICA
CM 1850 cryotome (Meyer Instruments Inc., Houston, TX, USA).
Serial tissue sections were placed onto poly-L-lysine-coated slides
(Polysciences Inc., Warrington, PA, USA). Consecutive tissue
sections were cut at the largest circumference of the tumour. The
sections were fixed in 4% paraformaldehyde in PBS (pH 7.2) for 1h
and incubated in the presence of primary antibodies. Primary
antibody signals were visualised and enhanced by fluorescence-
conjugated secondary antibodies to obtain sufficient fluorescence
signal for imaging. Sections were rinsed three times for 2min in
PBS between each consecutive step of the staining procedure.
Unless stated otherwise, all antibodies were diluted in PBS with
0.1% bovine serum albumin and 0.1% Tween-20 (PBS-BT).
Omission of the primary antibody served as a negative control.
p-PDGFR-b Tissue sections were incubated overnight at 41C with
goat polyclonal antibody to p-PDGFR-b (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) diluted 1:400. The sections were then
incubated for 1h at room temperature with Texas Red-conjugated
donkey anti-goat 1:200 (Jackson Immunoresearch, West Grove,
PA, USA).
EF5 Tumour hypoxia was assessed immunohistochemically. EF5,
a 2-nitroimidazole, is selectively retained in hypoxic tissues
because it is metabolised to a free radical form in cells that binds
to proteins to form specific residues in tissue that can be
recognised by antibodies (Yuan et al, 2006). EF5 binding was
visualised using a fluorochrome (Cy3) conjugated to the ELK3-51
antibody. The sections were incubated for 1h, with mouse
monoclonal antibody diluted 10mlml
 1 (Jackson Immunore-
search, PA, USA).
Endothelial cell marker (CD-31) Tissue sections were incubated
overnight at 41C with rat anti-mouse CD31 antibody (BD
Biosciences, San Jose, CA, USA) diluted 1:200 and then incubated
for 1h at room temperature with FITC-conjugated goat anti-rat
antibody 1:100.
VEGF
Endogenous peroxidase activity was quenched with 3% hydrogen
peroxide for 15min. Tumour sections were then blocked with 10%
donkey serum for an additional 15min. Sections were incubated
overnight at 41C with rabbit polyclonal antibody against VEGF
diluted 1:100 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
After rinsing 3 5min with PBS, biotinylated donkey anti-rabbit
antibody (Jackson Immunoresearch, PA, USA) was applied for
30min at room temperature. The slides were washed with PBS for
3 5min, followed by application of an avidin–biotin complex
(Vectastain ABC kit, Vector Lab Inc., Burlingame, CA, USA).
Location of the reaction was visualised with 3, 30-diaminobenzi-
dine tetrahydrochloride (DAB chromogen, Vector Lab Inc.,
Burlingame, CA, USA).
Image analysis
The tumour sections were quantitatively analysed with a
semiautomatic method based on a computerised digital image
analysis system. A high-resolution intensified solid-state camera
on a fluorescence microscope (Axioskop Zplus, Carl Zeiss Inc.,
Germany) with a computer-controlled motorised stepping stage
was used. Each tumour cross-section was sequentially scanned two
times at  50 magnification, using different filters for the FITC
(green) and Texas Red and Cy3 (red) signals.
After each scan, a high-resolution composite digital image was
reconstructed from the individual microscopic fields. The whole
scanning procedure thus yielded two composite images from each
tumour section. The thresholds for positive staining were set to be
background staining for each individual marker.
Haematoxylin and eosin staining on previously immunostained
sections permitted contour lines to be drawn around the tumour
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quantitative analysis of each marker. The positively stained regions
(EF5 or p-PDGFR-b) were segmented using a single threshold
value for all slides and all areas 42pixels (72mm
2) in size were
considered as positive regions. The stained fraction (%) for each
marker was then calculated by dividing the stained area by the
total area to give the hypoxic fraction and the relative p-PDGFR-b
expression. To assess mean vessel density (MVD), the number of
vessels, determined by positive CD31 staining, were counted in
6–8 fields and averaged to get a mean value for each tumour. The
representative images for publication have been adjusted for
brightness, contrast and colour balance for ease of viewing, but
quantification was performed without any manipulation of the
above-mentioned parameters.
Statistical analysis
The paired-t-test was applied to compare pre- and post-treatment
IFP measurements between groups. A two-sample t-test was used
to compare saline and Imatinib groups relative to the following
outcome measures: PDGFR-b, EF5, EGF and MVD. Pearson’s
correlation, or simple linear regression, was used to examine the
relationship between outcome measures within each treatment
arm. Data are presented as mean7s.e.m. Significant differences
between groups were determined with a Student t-test. In all cases,
Pp0.05 was considered statistically significant.
RESULTS
Before the initiation of experiments, it was determined that the
A549 xenograft overexpressed p-PDGFR-b (Figure 1A). After 4
days of treatment, the percentage of expression of p-PDGFR-b in
tumour sections was 2672.5% (mean7s.e.m.) for control samples
and 1372.2% (mean7s.e.m.) for the Imatinib-treated group. This
decrease in p-PDGFR-b expression after Imatinib treatment was
statistically significant (P¼0.001) (Figure 1B).
To determine whether downregulation of p-PDGFR-b affects
tumour angiogenesis, immunohistochemisty studies were per-
formed to determine VEGF and CD31 expression (Figure 2A).
0
5
10
15
20
25
30
35
40
Control Imatinib
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
p
-
P
D
G
F
R
-

(
%
 
a
g
e
 
o
f
 
s
t
a
i
n
i
n
g
)
 
P =0.001
0
5
10
15
20
25
Control Imatinib
%
 
A
g
e
 
o
f
 
h
y
p
o
x
i
a
 
(
E
F
5
)
 
P =0.008
A
B C
Control Imatinib
p-PDGFR-
EF-5
Figure 1 (A) Photomicrographs of p-PDGFR-b expression and tumour hypoxia (EF5) in control and after treatment with Imatinib. (B) p-PDGFR-b
expression in tumour after 4 consecutive days of treatment with Imatinib (50mgkg
 1) (mean7s.e.m.). (C) Tumour hypoxia after 4 days of treatment with
Imatinib (50mgkg
 1) (mean7s.e.m.)
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sVEGF was located primarily intracellularly, with less intense
staining in tumour stroma. After treatment with Imatinib, VEGF
expression was reduced from 31 to 15% positive area (P¼0.004)
(Figure 2C). Mean vessel density was reduced in Imatinib-treated
animals. Mean vessel density averaged 84717.7 and 44.176.7
(mean7s.e.m.) vessels per low-power field in control and
Imatinib-treated animals, respectively. This difference was statis-
tically significant (P¼0.05) (Figure 2D).
A change in tumour stromal density was also observed.
Figure 2A illustrates tumour stroma observed in the Imatinib-
treated and control groups, respectively (haematoxylin and eosin
stain). Stroma appears less dense in the Imatinib-treated vs the
control group. Interstitial fluid pressure measurements were taken
before and after 4 days of treatment. In controls, IFP averaged 1.4
and 2.1mmHg before and after sham treatment, respectively. This
difference was not significant (P¼0.27). The Imatinib group
exhibited similar pre-treatment values (1.5370.23mmHg). How-
ever, after 4 days of Imatinib treatment, IFP was reduced to
1.0970.2mmHg. This difference was statistically significant
(P¼0.036) (Figure 2B).
Imatinib-treated animals showed decreased levels of tumour
hypoxia, as assessed by EF5 immunohistochemistry (Figure 1A).
The percentage areas positive for EF5 were 1372.25 and 571.37%
(mean7s.e.m.) for the control and Imatinib-treated groups,
respectively (P¼0.008) (Figure 1C).
Relationships between IFP, p-PDGFR-b, EF5, VEGF and MVD
were examined after 4 days of Imatinib treatment. Interstitial fluid
pressure was positively correlated with EF5 staining (R
2¼0.81,
P¼0.008; Figure 3A). In addition, a positive correlation was found
between p-PDGFR-b and VEGF (R
2¼0.63, P¼0.004; Figure 3B).
Further, changes in IFP were also tested for correlation with
immunohistochemical parameters. A statistically significant rela-
tionship was observed between the change in IFP and MVD
(P¼0.01) (Figure 3C). This finding suggests that human NSCLC
xenografts with higher MVD are more likely to exhibit a decrease
in IFP following treatment with Imatinib.
DISCUSSION
To our knowledge, this is the first study to demonstrate that the
use of Imatinib in NSCLC xenografts results in decreased p-
PDGFR-b and VEGF expression. These changes in turn affected
angiogenesis (i.e. MVD), IFP and oxygenation. The increase in
tumour oxygenation following Imatinib treatment was most likely
due to a combination of these effects.
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Figure 2 (A) Cross-section of NSCLC xenografts, haematoxylin and eosin stain. After treatment with Imatinib tumour, stroma appears less compacted
and has loosened interstitial space compared to control; VEGF expression in control and in Imatinib-treated NSCLC xenografts; and vascular density
measured by CD31 staining. (B) Tumour interstitial fluid pressure after 4 days of Imatinib therapy. (C) VEGF expression in Imatinib-treated groups
(mean7s.e.m.). (D) Microvessel density after treatment with Imatinib (mean7s.e.m.).
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sAberrant tumour angiogenesis results in tortuous, leaky and
nonfunctional tumour vasculature. The aberrancies in vascular
structure and function play a crucial role in tumour growth and
metastasis. For instance, therapeutic drug delivery is impaired
thereby reducing treatment effectiveness and patient prognosis
(Folkman, 1995).
Vascular smooth muscle cells and pericytes are essential
for early growth of neovessels (Carmeliet, 2000). Phospho-
rylated PDGFR-b plays a crucial role in smooth muscle cell
and pericyte recruitment. In normal angiogenic processes,
interaction of these cells with ECs consequently results in
stabilisation of the capillary wall (Hellstrom et al, 1999). VEGF,
an EC-specific angiogenic cytokine, has been shown to induce EC
proliferation and migration, increase vascular permeability,
stimulate disassociation of pericytes from vascular endothelium
(Morikawa et al, 2002) and act as a key survival factor for EC
(Gerber et al, 1998). It has been shown that simultaneous
inhibition of multiple key regulatory factors of angiogenesis
(p-PDGFR-b, its ligand PDGF and VEGF) will decrease the
percentage of tumour vessels with pericyte coverage, induce EC
apoptosis and tumour regression (Shaheen et al, 2001). Interest-
ingly, more mature vessels are largely resistant to p-PDGFR-b
and VEGF inhibition (Bergers et al, 2003).
Data from this study shows that Imatinib reduces tumour
angiogenesis, presumably through simultaneous p-PDGFR-b
inhibition and VEGF downregulation. Whether or not this effect
occurs preferentially on more immature blood vessels cannot be
determined from this work because CD31, the EC marker used in
this study, stains both mature and immature ECs.
Increased IFP within a tumour is a result of the tumour’s highly
permeable microvascular network and the absence of a functioning
lymphatic system. Solid stress, generated by tumour cells growing
in a confined space, also contributes to elevated IFP (Netti et al,
1996; Griffon-Etienne et al, 1999). At steady state, the pressure
difference between the intravascular and interstitial spaces is near
zero (Boucher and Jain, 1992). The loss of a pressure gradient
across the vessel wall hinders capillary-to-interstitium drug
transport (Netti et al, 1999). Increased IFP relates to a greatly
diminished pressure differential between tissue and capillaries
than exists under normal physiological conditions. The results
from this study strongly support existing preclinical data
demonstrating that IFP can be lowered with p-PDGFR-b inhibition
using Imatinib (Pietras et al, 2001). Our data showed that in
Imatinib-treated NSCLC tumours, the abundance of tumour
stroma was significantly lowered, which might, as a result, impact
intratumoral pressure (Figure 2A).
Tumour hypoxia is an independent predictive factor for distant
metastasis and poor treatment outcome. Hypoxia can lead to
ionising radiation and chemotherapy resistance by depriving
tumour cells of the oxygen essential for the cytotoxic activities of
these agents (Airley et al, 2005; Greijer et al, 2005). Furthermore,
tumour hypoxia is associated with poor overall and disease-free
survival, greater disease recurrence and less locoregional control in
head and neck cancer, cervical carcinoma and soft-tissue sarcomas
(Brizel et al, 1999; Birner et al, 2000; Bachtiary et al, 2003; Harrison
and Blackwell, 2004). In addition, a statistically significant
relationship between IFP and tumour oxygenation has been
demonstrated in breast cancer patients (Taghian et al, 2005). In
an animal model of metastatic prostate cancer, animals treated
with Imatinib plus paclitaxel had significantly smaller tumours,
and fewer bone and lymph node metastasis than mice treated with
placebo or paclitaxel alone (Uehara et al, 2003). These mice also
expressed less activated PDGFR in tumour and tumour-associated
ECs, had less tumour cell proliferation and had significantly more
apoptotic cells than control mice (Uehara et al, 2003). Statistical
analysis of our data indicated a significant, linear relationship
between tumour IFP and hypoxia, as measured by EF5 hypoxia
marker.
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Figure 3 (A) IFP was positively correlated with EF5 (R
2¼0.63, P¼0.008). (B) Higher levels of p-PDGFR-b were associated with higher levels of
VEGF (R
2¼0.63, P¼0.004). (C) There was a positive correlation between increases in IFP and levels of MVD (P¼0.01).
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sWe argue that drug delivery could be improved by p-PDGFR-b
inhibition and decrease of IFP. A clinical trial investigating the
role of Imatinib as an adjunct to chemotherapy in patients with
metastatic, PDGFR-b-positive, NSCLC is ongoing. The working
hypothesis of the study is that blockade of PDGFR-b will change
IFP and subsequently effect tumour perfusion/permeability, drug
delivery and treatment response. Further, by improving tumour
oxygenation, we hope to enhance the cytotoxic and radiation
therapeutic effect in cancer patients, improve patients’ treatment
response and increase overall survival. Further preclinical studies
are in place to evaluate a potentially pertinent clinical role for a
p-PDGFR-b inhibitor as a radiation sensitiser (Figure 4).
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